TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05550909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine combination
Description: Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate-amodiaquine combination
Description: Tablets containing 50mg/135 mg or 100mg/270 mg of artesunate/amodiaquine will be administered according to weight as per manufacturer guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate
Description: The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Phosphate
Description: The single dose of 0.25mg/kg PQ will be administered in an aqueous solution, according to a standard operating procedure (SOP) provided by the manufacturer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Tablets containing 20 mg artemether and 120 mg lumefantrine will be administered according to weight as per manufacturer guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amodiaquine
Description: Tablets containing 153 mg of amodiaquine will be administered according to weight, aiming for a dosage of approximately 10 mg (7.7-15.3mg)/kg/day, given once or twice daily (together with artemether-lumefantrine) for three days.
Study: NCT06642207

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: to compare platelet count in Ankylosing Spondylitis patients in treatment with Anti-TNF- α and patients with IL17 Inhibitor

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC
Description: to compare platelet count in Ankylosing Spondylitis patients in treatment with Anti-TNF- α and patients with IL17 Inhibitor
Study: NCT05026125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Injection
Description: Injection of 3 μg/kg (Ideal Body Weight) of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Injection plus 30%
Description: Injection of 3 μg/kg (Ideal Body Weight) plus 30% of Remifentanil in the induction phase of anesthesia for orotracheal intubation for bariatric surgery
Study: NCT06067334

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full arch implant supported screw retained restoration with conventional impression technique
Description: surgical procedures: Implant installation Prosthetic procedures: Conventional impression fabrication of full arch implant supported screw-retained restoration evaluation: Accuracy, Passive fit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: full arch implant supported screw retained restoration with conventional digital technique
Description: surgical procedures: Implant installation Prosthetic procedures: Digital impression fabrication of full arch implant-supported screw-retained restoration evaluation: Accuracy, Passive fit
Study: NCT05606289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crisis Intervention Team (CIT) training
Description: Standard 40-hour CIT training given in one week.
Study: NCT06023888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mapping strategy
Description: The ablation strategy was based on the mapping results of periodicity.

Intervention type: OTHER
Group type: OTHER
Intervention: Mapping strategy
Description: PVI+ non-PV trigger
Study: NCT05823519

Intervention type: DEVICE
Intervention: Endologix Ovation Alto Endograft
Description: Implantation of aorto-bisiliac ALTO endograft to exclude Abdominal Aortic Aneurysms
Study: NCT06412497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Mycophenolate mofetil (MMF) therapy will begin on day +5. For pediatric service patients dosing of MMF will be 15 mg/kg/dose (max = 1000 mg) three times daily. For adult service patients dosing of MMF will be 15 mg/kg/dose (max = 1500 mg) twice daily. The same dosage is used orally or intravenously. Consider dose modification and/or pharmacokinetic measurements if renal and/or hepatic impairment (GFR\<25 mL/minute corrected). Stop MMF at Day +35 or 7 days after engraftment achieved (ANC\>500 x 106 neutrophils/L x 3 days) if later than day +35. If sufficient acute GvHD is observed to require systemic therapy, MMF should be continued for 7 days after initiation of systemic therapy. Afterward, use of MMF is at the discretion of the treating physician.
Study: NCT05783479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol
Description: estradiol 0.5 mg in vaginal cream twice daily for 10 days pre-procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid
Description: hyaluronic acid 5 mg in vaginal gel twice daily for 10 days pre-procedure
Study: NCT04812106

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT04958980

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Specific and educational guidelines on care for pathology (diabetes mellitus) according to each profession involved in the research
Description: Physician: Guidance on pathology, sequelae and treatment, as well as guidance on the importance of medical monitoring.~Dental surgeon: guidance on oral health, demonstration of brushing techniques and daily flossing and periodontal changes resulting from diabetes mellitus.~Nurse: Guidance on pathology prioritizing pathophysiology, self-care and skin care and wound prevention (vascular sequelae).~Nutritionist: nutritional guidelines on diabetes mellitus and healthy eating habits.~Physiotherapist: guidance on prevention of falls and injuries and health promotion.~Physical educator: guidance on the importance of practicing physical activities for general health, encouraging self-care and body awareness and demonstrating basic physical activities that can be performed at home.
Study: NCT04905602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905/placebo
Description: Drug: SHR-1905 subcutaneous, single dose~Drug: Placebo subcutaneous, single dose
Study: NCT06441981

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education
Description: Educational material brochures will be given to 800 respondents. Educational material is provided via WhatsApp chatbot. After being educated, respondents were given a test to determine the increase in understanding of the material.
Study: NCT06119607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRIFLO Heart Valve
Description: Surgical Aortic Valve Replacement - Mechanical Valve
Study: NCT06547125

Intervention type: DEVICE
Group type: OTHER
Intervention: JUVÉDERM® VOLITE™
Description: Injection, intradermal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM® VOLITE™
Description: Injection, intradermal

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No-treatment control
Study: NCT04696354

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IVUS
Description: Those who are randomized to the interrogation arm will have diagnostic imaging performed by IVUS to determine their treatment plan.

Intervention type: OTHER
Group type: OTHER
Intervention: Continued Compression Therapy/Stockings
Description: Those who are randomized to the deferred interrogation arm while continue compression therapy as prescribed.
Study: NCT04991077

Intervention type: BIOLOGICAL
Intervention: analyse of angiogenic, vasoactive and VEGF systems
Description: the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.

Intervention type: BIOLOGICAL
Intervention: analyse of angiogenic, vasoactive and VEGF systems
Description: the angiogenic, vasoactive and VEGF systems will be analysed through blood and urine sampling. These samples will be collected at the time of malignant hypertension diagnosis and repeated one month later, in 30 patients (patients group). The same tests will be performed once in 15 patients with severe non-malignant hypertension, constituting the control group.
Study: NCT06474988

Intervention type: OTHER
Intervention: Skin tests
Description: Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests

Intervention type: OTHER
Intervention: Skin tests
Description: Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests

Intervention type: OTHER
Intervention: Skin tests
Description: Acquisition of Skindex questionnaire 29 and execution of instrumental skin tests
Study: NCT05892276

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trauma Memory Reactivation
Description: Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma Memory Reactivation
Description: Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.
Study: NCT05772975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H-PRF (Horizontal-platelet rich fibrin)
Description: Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. it serves as a biological healing matrix by supporting cell migration and cytokine release. H-PRF is obtained by horizontal centrifugation using (Bio-PRF) centrifuge on 700 g force for 8 minutes. This way the cells separate much more efficiently throughout the entire membrane/clot.
Study: NCT05892276

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Trauma Memory Reactivation
Description: Participants will be guided through the trauma memory reactivation paradigm by the study staff. The trauma memory reactivation paradigm entails two distinct procedures: (1) participants will watch a video clip related to their trauma; then (2) describe a verbal narrative of their traumatic event for approximately 5 minutes to a research team member.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD) Broad-Spectrum Oil
Description: 300mg CBD broad-spectrum oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Broad-Spectrum Oil
Description: 300mg CBD broad-spectrum oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: 3ml oral dose of medium-chain triglycerides (MCT) coconut oil.
Study: NCT06458036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib Monotherapy
Description: Patients will receive selpercatinib monotherapy for 6 months at the FDA-approved dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I Therapy
Description: Patients will receive 131I therapy after 6 months of selpercatinib.
Study: NCT06575972

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: JoyRise Recovery Powder
Description: JoyRise Recovery Powder is a dietary supplement that contains Dihydromyricetin (DHM) and other natural ingredients. It is designed to mitigate the aftereffects of alcohol consumption. Participants will mix one serving in 8-12 oz of water and consume it the morning after alcohol consumption.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo solution that is visually and tastefully similar to JoyRise Recovery Powder but contains no active ingredients. It will be mixed in 8-12 oz of water and consumed the morning after alcohol consumption.
Study: NCT05772975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E-PRF
Description: Platelet-rich fibrin is an autologous biomaterial originating from human blood following centrifugation without additives that contains supraphysiological doses of growth factors. In order to extend its resorption period heating method is used. After centrifugation of blood using (Bio-PRF) centrifuge on 700 g force for 8 minutes top layer is heated for 10 minutes at 75°C in BIO-Heat device. When cooled it is mixed with cell rich buffy coat. This way PRF with extended life is obtained.
Study: NCT05105802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention
Description: Using AmDtx MBI-based app, targeted MBI training will consist of a 4-week custom-made program that include, setting intentions and check-in with mood, audio-recorded lectures, guided meditations such as body scans, and writing events journal (Appendix 5). Each standardized course will be unlocked as the child progresses through the program. Users will be encouraged to participate in the app-based activities for a total of 10-15 minutes every day, with a minimum of 4 days in a week, over a period of 4 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Sham + Usual Care
Description: Usual care recommends that the patient refrain from physical and cognitive activities for 24-48 hours after injury. After the rest period, it is recommended that low to moderate levels of physical and cognitive activity be gradually started 24-48 hours after injury. The activities should be performed at a level that does not result in recurrence or exacerbation of symptoms. Children must refrain from any activities that increase the risk of re-injury (drills with body contact or that risk falls) until fully asymptomatic and cleared by their primary care or other medical provider. The sham journey will consist of playing an open-source cognitive math game delivered through the same app as MBI, but without the mindfulness content.
Study: NCT06130046

Intervention type: BIOLOGICAL
Intervention: MR-proADM dosage
Description: Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U

Intervention type: BIOLOGICAL
Intervention: MR-proADM dosage
Description: Dosage of MR proADM at OLT/KT, 1, 3, 5, 15 POD and 1, 3, 6, 9, 12 months F-U
Study: NCT06229834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic Care
Description: The chiropractic care protocol can be personalized to the patient's clinical needs and follows the scope of chiropractic care practice in the Commonwealth of Massachusetts and the State of Connecticut. Components of the chiropractic intervention include: posture correction / spinal stabilization exercises; soft tissue relaxation techniques; spinal manipulation (i.e. chiropractic adjustment) / mobilization; breathing and relaxation techniques; stretches, self-care; ergonomic modifications; bracing and supports.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Headache Health Education
Description: Material to be covered will focus on pre-defined migraine specific topics including materials we have previously used in a popular Osher Clinical Center patient education program called the Migraine Toolkit. Sessions will be delivered by trained research assistants and will utilize publicly available short videos followed by scripted discussions with the participant. Participants will be allowed to continue usual care throughout the study.
Study: NCT05972967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS906 Study Drug - 3 mg/kg
Description: All patients will receive 3 doses of OMS906 of 3 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS906 Study Drug - 5 mg/kg
Description: All patients will receive 3 doses of OMS906 of 5 mg/kg Intravenous (IV) at 8-week intervals. Clinical responders at Week 24 will receive an additional 3 doses of OMS906 only at 8-week intervals (monotherapy). Incomplete responders may receive an additional 3 doses of OMS906 with ravulizumab at 8-week intervals. Non responders will not receive additional OMS906.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants must be on prescribed stable dose of ravulizumab (IV dose per approved summary of medicinal product characteristics) for at least 2 doses (4 months) prior to baseline. During the Run-in period - ravulizumab only. During the Treatment period all patients will receive 3 doses of ravulizumab at 8-week intervals. Clinical responders at Week 24 will not receive additional ravulizumab. Incomplete responders may receive an additional 3 doses of ravulizumab with OMS906 at 8-week intervals. Non responders will return to treatment with ravulizumab or standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Participants must be on prescribed stable dose of ravulizumab (IV dose per approved summary of medicinal product characteristics) for at least 2 doses (4 months) prior to baseline. During the Run-in period - ravulizumab only. During the Treatment period all patients will receive 3 doses of ravulizumab at 8-week intervals. Clinical responders at Week 24 will not receive additional ravulizumab. Incomplete responders may receive an additional 3 doses of ravulizumab with OMS906 at 8-week intervals. Non responders will return to treatment with ravulizumab or standard of care.
Study: NCT06168292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ID-RFA and Radiotherapy
Description: The histologic or cytologic examination will be performed at the time of the first biliary drainage, and the extent of the cholangiocarcinoma lesion will be assessed during the procedure. After the diagnosis of extrahepatic cholangiocarcinoma, ID-RFA will be performed, and a biliary stent will be inserted for biliary drainage. Radiotherapy will be performed within 1 month of ID-RFA.
Study: NCT06350929

Intervention type: OTHER
Intervention: Cardiac output monitoring by the Starling™ SV Sebac®
Description: During the surgery, the channels and monitoring equipment will be set up according to the usual procedure in the vascular surgery department. As part of the research, the Starling™ SV Sebac® electrodes will be installed (to measure cardiac flow, cardiac index (CI), stroke volume (VES), variations in stroke volume (VVES), and peripheral resistors (TPRI)).~Once the equipment is in place, anesthetic induction will be carried out according to the usual protocol with curarization and mechanical ventilation.~If the appearance of arterial hypotension is noted after anesthetic induction and mechanical ventilation, the patient will be definitively included in the study. As recommended, he will receive norepinephrine to treat hypotension.~The measurements from the monitoring will be collected at 3, 5, and 10 min after the administration of norepinephrine.~10 days after admission to the operating room, hospitalization data will be collected.
Study: NCT05600348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork Consumption
Description: Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork Consumption
Description: Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pork Consumption
Description: Feeding of pork is controlled at 0, 3 or 6 oz per day for 4 weeks each in random order.
Study: NCT05753722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRTH-101
Description: PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRTH-101
Description: PRTH-101 is a humanized immunoglobulin gamma-1 (IgG1) monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: PRTH-101 in combination with Pembrolizumab